Chemotherapy with nivolumab in advanced gastro-oesophageal adenocarcinoma
Mené sur 1 581 patients atteints d'un adénocarcinome de l'oesophage, d'un cancer gastrique ou de la jonction oeso-gastrique de stade avancé ou métastatique, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout du nivolumab à une chimiothérapie de première ligne
Platinum and fluoropyrimidine combination chemotherapy forms the basis of first-linesystemic treatment for advanced gastric, gastro-oesophageal junction, and oesophagealadenocarcinoma, and apart from the addition of trastuzumab for the 15% of patientswhose tumours are HER2-positive, there has been very little progress over the past two decades. The median overallsurvival (OS) of patients with advanced disease is around 11 months.
The Lancet 2021